» Articles » PMID: 25171128

β-Caryophyllene Ameliorates the Alzheimer-like Phenotype in APP/PS1 Mice Through CB2 Receptor Activation and the PPARγ Pathway

Overview
Journal Pharmacology
Publisher Karger
Specialty Pharmacology
Date 2014 Aug 30
PMID 25171128
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: The activation of cannabinoid receptor 2 (CB2) has the beneficial effect of reducing neuroinflammatory response in the treatment of Alzheimer's disease (AD) and is suggested to trigger the peroxisome proliferator-activated receptor-γ (PPARγ) pathway; agonists of both receptors improve AD. Recently, the plant metabolite β-caryophyllene was shown to selectively bind to CB2 receptor and act as a full agonist.

Methods: In this study, we examined the anti-inflammatory effect of β-caryophyllene in a transgenic APP/PS1 AD model and analyzed whether this effect was mediated by CB2 and PPARγ.

Results: β-Caryophyllene, given orally, prevented cognitive impairment in APP/PS1 mice, and this positive cognitive effect was associated with reduced β-amyloid burden in both the hippocampus and the cerebral cortex. Moreover, β-caryophyllene reduced astrogliosis and microglial activation as well as the levels of COX-2 protein and the mRNA levels of the proinflammatory cytokines tumor necrosis factor-α and interleukin-1β in the cerebral cortex. The use of the CB2 antagonist AM630 or the PPARγ antagonist GW9662 significantly reversed the protective effects of β-caryophyllene on APP/PS1 mice.

Conclusion: These results demonstrate that the anti-inflammatory effect of the sesquiterpene β-caryophyllene involves CB2 receptor activation and the PPARγ pathway and suggest β-caryophyllene as an attractive molecule for the development of new drugs with therapeutic potential for the treatment of AD.

Citing Articles

Exploring the diversity of cannabis cannabinoid and non-cannabinoid compounds and their roles in Alzheimer's disease: A review.

Doumar H, Mostafi H, Elhessni A, Touhami M, Mesfioui A IBRO Neurosci Rep. 2025; 18:96-119.

PMID: 39866750 PMC: 11763173. DOI: 10.1016/j.ibneur.2024.12.011.


Deep learning-based drug screening for the discovery of potential therapeutic agents for Alzheimer's disease.

Wu T, Lin R, Cui P, Yong J, Yu H, Li Z J Pharm Anal. 2025; 14(10):101022.

PMID: 39850238 PMC: 11755336. DOI: 10.1016/j.jpha.2024.101022.


Exploring β-caryophyllene: a non-psychotropic cannabinoid's potential in mitigating cognitive impairment induced by sleep deprivation.

Lim C, Ogawa S, Kumari Y Arch Pharm Res. 2024; 48(1):1-42.

PMID: 39653971 DOI: 10.1007/s12272-024-01523-z.


Microglial cannabinoid receptor type II stimulation improves cognitive impairment and neuroinflammation in Alzheimer's disease mice by controlling astrocyte activation.

Sobue A, Komine O, Endo F, Kakimi C, Miyoshi Y, Kawade N Cell Death Dis. 2024; 15(11):858.

PMID: 39587077 PMC: 11589152. DOI: 10.1038/s41419-024-07249-6.


A Comprehensive Exploration of the Multifaceted Neuroprotective Role of Cannabinoids in Alzheimer's Disease across a Decade of Research.

Tyrakis P, Agridi C, Kourti M Int J Mol Sci. 2024; 25(16).

PMID: 39201317 PMC: 11354546. DOI: 10.3390/ijms25168630.